Hannah Boam

Researchers An, Valeria and Simon are thousands of miles apart. But they all share the same goal: to solve the mystery of what causes MS progression.

Dr Emma Gray, our Assistant Director of Research, and Sasha Leigh, who lives with MS, reflect on what research has achieved in recent years.

Lauren Taylor, a Clinical Psychology PhD student, told us about the NEuRoMS project. It aims to change how cognitive MS symptoms are managed.

The ADAMS study is investigating how genes affect the risk of getting MS in people from different ethnic backgrounds. Three people involved told us why the study is so important.

We asked a few people with MS what motivated them to take part in some of our research studies and what their experience was like.

It can be tricky to find out which studies are recruiting. And it can be daunting to sign-up if you don’t know what research usually involves. So we’ve answered some of the most common questions we get asked about taking part in research.

A new immunotherapy treatment in a trial for progressive MS hit the headlines recently. News reports say it could reverse or stabilise the progression of MS by targeting the Epstein-Barr virus (EBV). We looked behind the headlines to find out more.

MRI technology has been evolving. Techniques are faster and more powerful than ever. And researchers are making the most of this new technology so we can stop MS sooner. Find out how we've been using it in our trials.

Hannah is a Research Communications Officer. She tells us the ins and outs of research communications at the MS Society and why it’s such a rewarding job.

Is it better to start with highly intensive MS treatment straight after diagnosis? It’s a question on many a neurologist’s lips and something the DELIVER-MS trial hopes to answer. We spoke to three people involved in the trial to find out what this means.